Live Analytics
Comments 0
Paxlovid, evidence base? Analytics Table
Income Estimates for Paxlovid, evidence base?
Based on this YouTube video's total view count of 445K views and industry-standard rates, the estimated total earning is $312 - $891 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.
About Paxlovid, evidence base?
Explore Paxlovid, evidence base? with 445,515 views, 11,540 likes, and 2,610 comments. Experience the impact of this video content that has captured audience attention.
Paxlovid, it this an evidence based intervention in May 2022? Paper FDA EMU was based on https://www.nejm.org/doi/full/10.1056/NEJMoa2118542 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) 1120 patients received nirmatrelvir plus ritonavir 1126 received placebo Relative risk reduction Risk of progression to severe Covid-19, 89% lower than the risk with placebo Absolute risk reduction https://www.precisionvaccinations.com/what-paxlovids-absolute-and-relative-covid-19-risk-reduction 7% down to 1% symptomatic, unvaccinated, non hospitalized adults at high risk for progression to severe coronavirus disease 2019 July 16 and December 9, 2021 If vaccinated people and previously infected people are partly protected More people would need to be treated to prevent one adverse event Pfizer press release (5th November 2021) https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate our oral antiviral candidate, … has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations Pfizer Shares In Vitro Efficacy of Novel COVID-19 Oral Treatment Against Omicron Variant https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-vitro-efficacy-novel-covid-19-oral-treatment https://www.yalemedicine.org/news/12-things-to-know-paxlovid-covid-19 https://www.fda.gov/media/155051/download The results showed in all cases that nirmatrelvir was a potent inhibitor of its target. PAXLOVID™ for Post-Exposure Prophylactic Use https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-top-line-results-phase-23-epic-pep-study Evaluated data from 2,957 adults Pfizer observed risk reductions of 32% (5 day course) 37% reduction (10 day course) These results, however, were not statistically significant and, as such, the primary endpoint of reducing the risk of confirmed and symptomatic COVID-19 infection in adults who had been exposed to the virus through a household contact was not met. FACT SHEET FOR PATIENTS, PARENTS, AND CAREGIVERS EMERGENCY USE AUTHORIZATION (EUA) OF PAXLOVID FOR CORONAVIRUS DISEASE 2019 (COVID-19) https://www.fda.gov/media/155051/download PAXLOVID is not an FDA-approved medicine in the United States. PAXLOVID is an investigational medicine Some medicines may interact with PAXLOVID and may cause serious side effects. If you take too much PAXLOVID, call your healthcare provider or go to the nearest hospital emergency room right away. Possible side effects of PAXLOVID are: Allergic Reactions trouble swallowing or breathing, swelling of the mouth, lips, or face, throat tightness, hoarseness, skin rash Liver Problems. Tell your healthcare provider right away, loss of appetite, yellowing of your skin and the whites of eyes (jaundice), dark-colored urine, pale colored stools and itchy skin, stomach area (abdominal) pain. Other possible side effects include: altered sense of taste, diarrhea, high blood pressure, muscle aches Dr. Ashish K. Jha, White House, Covid-19 coordinator The new White House Covid czar says avoiding all virus infections isn’t the goal of U.S. pandemic policy. Paxlovid, push to reach the vulnerable Doctors are too hesitant to prescribe the drug https://en.wikipedia.org/wiki/Ashish_Jha Senior Advisor at Albright Stonebridge Group https://www.politico.com/newsletters/transition-playbook/2021/03/23/the-blob-abides-492214 The firm advises clients on international policy and global markets Patrick Vallance From 2012 to 2018, he was President of Research and Development at global pharmaceutical company, GlaxoSmithKline (GSK) https://www.telegraph.co.uk/news/2020/09/23/revealed-sir-patrick-vallance-has-600000-shareholding-firm-contracted/ Cashed £5,000,000 GSK shares Future jobs of FDA’s haematology-oncology reviewers https://www.bmj.com/content/354/bmj.i5055.full https://www.npr.org/sections/health-shots/2016/09/28/495694559/a-look-at-how-the-revolving-door-spins-from-fda-to-industry?t=1651600609470 More than a quarter of the Food and Drug Administration employees (who approved cancer and hematology drugs from 2001 through 2010) left the agency and now work or consult for pharmaceutical companies,
About YouTube Real-Time View Count
With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.
Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.
Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.
Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.
Embed Widget
Parameters:
fullscreen=true- Fullscreen countergraph=true- Live graph chartcounter=0/1/2- Select counter (0=likes, 1=views, 2=comments)
URL
Click to copy the embed URL to your clipboard

